Dr. David Reardon, MD – Boston, MA

  • Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma  

    David Reardon, MD, JAMA Oncology
  • Socioeconomic Disparities Associated with MGMT Promoter Methylation Testing for Patients with Glioblastoma  

    David Reardon, MD, JAMA Oncology
  • Effect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma  

    David A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
  • You Might Also Like